AlzeCure is part of the region’s world-leading research in healthy aging

Invest Stockholm has now updated its presentation of the region’s research and the companies working with neurodegenerative diseases. Here you will find, among others, AlzeCure, which is developing a painkiller based on this year’s Nobel Prize in Medicine.

Stockholm-Uppsala holds world-leading knowledge in the field of healthy aging. Invest Stockholm has made an extensive review of the region’s academic research in an updated report that also includes several selected companies.

Here is one of Flemingsberg’s knowledge companies: AlzeCure, which develops new innovative drug therapies for the treatment of severe diseases that affect the central nervous system, such as Alzheimer’s disease and pain.

The company is developing a painkiller based on a discovery by David Julius and Ardem Patapoutian who share this year’s Nobel Prize in Physiology or Medicine.

Read more about AlzeCure and the region’s leading research in the report: Improving Quality of Life for People with Neurodegenerative Diseases (pdf).

DreamHack 2025: When Visibility Becomes a Strategic Asset for Early-Stage Game Studios

DreamHack Stockholm is not just a festival. It is one of the few occasions in Sweden where audiences, creators, and the industry move within the same space at the same time. In 2025, DreamHack set a new attendance record with over 60,000 visitors at Stockholmsmässan in Älvsjö, with attendees coming from 70 countries. This year, Press Start Game Hub, the game initiative based in Flemingsberg, took part.

Limitless Potential: Winner of the Flemingsberg Science Award 2025

Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.

Do you want to know more?
Subscribe to our newsletter.

Do you want to know more?
Subscribe to our newsletter.

CF_logo_neg
2021-12-10T13:19:20+01:00
Go to Top